 | • レポートコード：MRC2303K046 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥665,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,225,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、世界の泌尿生殖器薬市場規模が、予測期間中（2022年-2027年）、CAGR 2.6％で増大すると予測されています。本レポートでは、泌尿生殖器薬の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患種類別（勃起不全、淋病、性器ヘルペス、尿路感染症、その他）分析、（ホルモン療法、子宮弛緩剤、尿道鎮痙薬、子宮刺激剤、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、Eli Lilly and Company、GlaxoSmithKline PLC、Cipla USA Inc.、Melinta Therapeutics Inc.、Allergan PLC、Merck & Co. Inc.、Novartis AG、Pfizer Inc.、Genentech, Inc.、Abbott Pharmaceutical、F. Hoffmann-La Roche Ltdなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の泌尿生殖器薬市場規模：疾患種類別 - 勃起不全における市場規模 - 淋病における市場規模 - 性器ヘルペスにおける市場規模 - 尿路感染症における市場規模 - その他疾患における市場規模 ・世界の泌尿生殖器薬市場規：薬剤種類別 - ホルモン療法の市場規模 - 子宮弛緩剤の市場規模 - 尿道鎮痙薬の市場規模 - 子宮刺激剤の市場規模 - その他薬剤の市場規模 ・世界の泌尿生殖器薬市場規模：地域別 - 北米の泌尿生殖器薬市場規模 アメリカの泌尿生殖器薬市場規模 カナダの泌尿生殖器薬市場規模 メキシコの泌尿生殖器薬市場規模 … - ヨーロッパの泌尿生殖器薬市場規模 ドイツの泌尿生殖器薬市場規模 イギリスの泌尿生殖器薬市場規模 フランスの泌尿生殖器薬市場規模 … - アジア太平洋の泌尿生殖器薬市場規模 中国の泌尿生殖器薬市場規模 日本の泌尿生殖器薬市場規模 インドの泌尿生殖器薬市場規模 … - 南米/中東の泌尿生殖器薬市場規模 南アフリカの泌尿生殖器薬市場規模 ブラジルの泌尿生殖器薬市場規模 アルゼンチンの泌尿生殖器薬市場規模 … ・競争状況 ・市場機会・将来動向 |
The Genitourinary Drugs Market is poised to grow at a CAGR of 2.6% during the forecast period (2022-2027).
The unprecedented increase in coronavirus-infected patients had reduced access to other primary care services and resulted in a significant drop in non-COVID-19-related diagnoses, such as genitourinary tract infection. According to the article published in the Asian Journal of Urology in July 2021 titled ‘SARS-CoV-2Eeffects in the Genitourinary System and Prospects of Sex Hormone Therapy’, coronaviruses can cause urological symptoms when they infect the genitourinary system. COVID-19 is responsible for genitourinary organ dysfunction and damage. Patients with COVID-19 have been found to have kidney impairment in several studies. In addition, according to the study published in the International Journal of Environmental Research and Public Health in April 2020 by Jing Qi, Yang, COVID-19 infection poses the greatest threat to the respiratory, digestive, and reproductive systems. Thus, the genitourinary market is significantly impacted by COVID-19.
The growing prevalence of genitourinary disorders such as renal failure, benign prostatic hyperplasia (BPH), end-stage renal disease (ESRD), erectile dysfunction, and an increasing number of pipeline drugs is expected to widen the market growth globally. According to the American Academy of Family Physicians (AAFP) in March 2020, by Leonardo Ferreira, kidney stones are a common ailment, with an annual incidence of eight per 1,000 persons. Furthermore, as per the same source, around 13% of men and 7% of women may develop a kidney stone during their lifetime, and the total incidence of urinary retention in the United States is 4.5 – 6.8 per 1,000 men. Hence, an increase in renal failure drive market growth.
Furthermore, rising disposable incomes, continuous improvements in healthcare infrastructure, increased investments in R&D activities for developing novel molecules for treating genitourinary diseases, and an increasing number of pipeline drugs are expected to drive the market during the forecast period. For instance, in February 2022, Asieris Pharmaceuticals received the clinical trial application (CTA) approval for Hexvix, a drug for the diagnosis of bladder cancer, from the National Medical Products Administration (NMPA) of China.
However, increasing counterfeit drugs and a lack of awareness about the infections and medications for treatment will restrain the market for genitourinary drugs.
Genitourinary Drugs Market Trends
Urinary Tract Infections Segment is Expected to Dominate the Genitourinary Drugs Market During the Forecasted Period
The weekly rate of UTI diagnosis fell slightly in 2020, which may have slowed the industry’s growth in recent months. According to the study published in the ADIAN Journal in December 2020, a significant decrease in Urinary tract infection (UTI) diagnoses due to the COVID-19 pandemic raises concern. The global pandemic changed primary care dramatically when people with COVID-19 were infected with SARS-CoV-2.
According to an article published in the International Journal of Molecular medicine in 2020, kidney stone disease, also known as nephrolithiasis or urolithiasis, is one of medicine’s oldest diseases. It is estimated that 11% of people will develop kidney stones at some point in their lives, and the prevalence and incidence of kidney stones are increasing worldwide. However, the overall prevalence of urolithiasis was 11.2%, with 48.8% of those surveyed having a first-degree relative with the disease. Males were 1.8 times more likely than females to have urolithiasis. Overall, the prevalence of complicated UTIs is set to increase during the forecast period, mainly owing to the increasing bacterial resistance in UTI cases and the rise in the recurrence rate for UTIs. Thus Kidney stone is the primary cause of UTI diseases, thereby boosting the segment.
Furthermore, in the United States According to the National Institute of Medicine in July 2020, urinary tract infection affects approximately 150 million people globally. In addition, about 11% of women visit one physician yearly for urinary tract infection treatment. Urinary tract infections (UTIs) are among the most common microbial diseases affecting people of all ages. Globally, UTIs affect around 150 million people every year. Diabetic patients have a higher risk of developing UTIs. With a global increase in the diabetic population, complications like dysuria and organ damage are associated with UTIs, which are also rising. This condition drives the segment by increasing sales of urinary tract infection medicines.
Additionally, the launch of more efficient combination drugs and the growing geriatric population is expected to boost the growth of the urinary tract infection therapeutics market. For instance, in February 2020, Allecra, a French pharmaceutical company, launched Exblifep, a combination of enmetazobactam, a novel extended-spectrum beta-lactamase inhibitor, and cefepime, a fourth-generation cephalosporin that met primary endpoints in a clinical trial for cUTIs.
Additionally, the genitourinary drugs market is expected to gain from increasing incidences of urinary diseases and related illnesses that are sexually transmitted. Moreover, rising concerns about urinary incontinence and impotency, as well as technological advancements in genitourinary devices, are anticipated to propel the growth of the global genitourinary drugs market over the forecast period.
North America is Expected to Dominate the Market During the Forecasted Period
North America is expected to dominate the genitourinary drugs market due to the rise in genitourinary disease cases, growing need for improved treatments and therapies of genitourinary diseases, and increasing awareness about genitourinary disorders in health care expenditure, and developing health care infrastructure in the region.
According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2021, in the United States, approximately 30 million men have erectile dysfunction (ED). Furthermore, the United States has the highest rate of self-reported ED compared to any other country. Thus, increasing the prevalence of ED in the United States is expected to drive market growth over the forecast period. In addition, According to the article published in Infectious Diseases Society of America in November 2020, by Pranita D. Tamma, during a routine checkup for a UTI, a woman was observed to be infected by E. coli that showed resistance to the last-resort antibiotic, Colistin. The discovery of Colistin-resistant bacteria was considered a major issue. Thus, the rising prevalence of genitourinary diseases will increase the demand for drugs to treat such conditions, thereby boosting the market growth.
According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2021, in the United States, approximately 30 million men have erectile dysfunction (ED). Furthermore, the United States has the highest rate of self-reported ED compared to any other country. Thus, increasing the prevalence of ED in the United States is expected to drive market growth over the forecast period. Thus, the rising prevalence of genitourinary diseases is anticipated to increase the demand for genitourinary drugs over the forecast period.
Furthermore, research and development of novel classes of antibiotics for urinary tract infections are expected to aid in market growth. In August 2020, for example, researchers at California Polytechnic State University announced the development of a new class of antibiotics for urinary tract infections that target bacterial iron acquisition.
Thus, all aforementioned factors are expected to boost the market in the region over the forecast period.
Genitourinary Drugs Market Competitor Analysis
Major market players are investing high capital in R&D and adopting many strategies, such as new product launches and developments, geographical expansions, collaborations, and acquisitions, to strengthen their market position in the global genitourinary drugs market. The major players include Merck and Co., Cipla Inc., Pfizer, Allergen, and Melinta Therapeutics Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Genitourinary Disorders
4.2.2 Rising Disposable Incomes and Constant Improvements in Healthcare Infrastructure
4.2.3 Increasing Number of Pipeline Products
4.3 Market Restraints
4.3.1 Lack of Therapy Compliance
4.3.2 Increasing Advent of Counterfeit Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Disease Type
5.1.1 Erectile dysfunction
5.1.2 Gonorrhoea
5.1.3 Genital Herpes
5.1.4 Urinary Tract Infections
5.1.5 Urinary Incontinence
5.1.6 Glomerulonephritis
5.1.7 Chronic renal failure
5.1.8 Other Disease Types
5.2 By Drug Type
5.2.1 Hormonal Therapy
5.2.2 Impotence Agents
5.2.3 Uterine Relaxants
5.2.4 Urinary Antispasmodics
5.2.5 Urinary pH Modifiers
5.2.6 Uterine Stimulants
5.2.7 Miscellaneous Genitourinary Tract Agents
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Eli Lilly and Company
6.1.2 GlaxoSmithKline PLC
6.1.3 Cipla USA Inc.
6.1.4 Melinta Therapeutics Inc.
6.1.5 Allergan PLC
6.1.6 Merck & Co. Inc.
6.1.7 Novartis AG
6.1.8 Pfizer Inc.
6.1.9 Genentech, Inc.
6.1.10 Abbott Pharmaceutical
6.1.11 F. Hoffmann-La Roche Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS